| gap-pubmed-20260410- | What is the direct molecular mechanism linking aconitine exposure to AMPK phosph | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | How do cytotoxic T cells specifically induce epileptogenic focal neural loss in | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the optimal therapeutic targets to prevent structural epileptogenesis i | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do some autoimmune encephalitis cases develop treatment-resistant epilepsy w | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific pathophysiological mechanisms linking Mfsd2a deficiency to | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How does LPC-DHA uptake mechanistically regulate de novo lipogenesis in brain an | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | What is the detailed molecular mechanism by which Mfsd2a transports lysophosphat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-pubmed-20260410- | How do brain vulnerability proteins identified in plasma mechanistically contrib | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms explain APOE's delirium risk independent of its established deme | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do APOE-mediated lipid metabolism changes translate to disease risk versus r | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms link APOE isoform differences to altered cell | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the identified SIRT6-NAMPT-CD38-HIF1A network interactions mechanisticall | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does SIRT6 inhibition show therapeutic potential when SIRT6 normally protect | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does nucleolin contribute to Alzheimer's disease pathology at the molecular | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive nucleolin's translocation from nucleus to cell surface in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-pubmed-20260410- | Why do some Danon disease patients present with atypical phenotypes lacking the | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link LAMP2 deficiency to the diverse arrhythmia phenotypes obser | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the complete signaling pathway from DHA to NPD1-mediated neuroprotection | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do RPE cells mechanistically contribute to photoreceptor cell death in retin | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which homeostasis is maintained in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does mTOR-mediated translational dysregulation specifically contribute to ne | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine mTOR's selectivity for specific target mRNAs | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do Aβ oligomers specifically target synapses while sparing other cellular st | open | 0.78 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which Aβ oligomers target and disr | open | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the long-term safety and efficacy profiles of astrocyte-targeted CRISPR | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does CRISPR-mediated miR-33 editing specifically restore ApoE lipidation at | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link miR-33 elevation to ApoE4-specific pathology in s | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do therapeutic effects persist for 6 months after single ds-cRNA administrat | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurotherapeutics |
| gap-pubmed-20260410- | What mechanisms link PKR inhibition to amyloid-β plaque reduction in AD models? | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do ds-cRNAs achieve selective PKR inhibition without affecting normal PKR fu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can ferroptosis inhibitors prevent BBB disruption and edema formation after card | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | How does ferroptosis mechanistically cause AQP4 depolarization and dysfunction? | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the temporal sequence linking iron overload to ferroptosis initiation in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does polyglutamine expansion affect huntingtin's KFERQ-like motif recognitio | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether mutant huntingtin is degraded by CMA versus other autoph | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does microglial phagocytosis become overwhelmed specifically in NMOSD compar | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the threshold between beneficial and pathological sTREM2 levels | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does sTREM2 mechanistically trigger microglial dysfunction through NF-κB sig | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does lysosomal pH elevation specifically cause the observed mitochondrial dy | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is SLC45A1 neuron-specific when other lysosomal proteins show broader cell-t | open | 0.77 | 0.00 | 2026-04-10 | 0 | | lysosomal-biology |
| gap-pubmed-20260410- | How does SLC45A1's dual role in sugar transport and V-ATPase stabilization mecha | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines VPA's differential effects on neuronal versus glial cell neuropr | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does VPA's HDAC inhibition mechanistically link to neuroprotection in neurod | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which aging hallmarks are primary drivers versus consequences in neurodegenerati | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the nine hallmarks of aging interact mechanistically to drive neurodegene | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why have biomarkers for distinguishing FTLD pathological subtypes in sporadic di | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms determine whether FTLD develops tau, TDP-43, or FET protein incl | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do dendritic spine deficits cause memory impairment in the absence of neuron | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | Why do memory deficits emerge before locomotor dysfunction despite both involvin | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link conformationally changed tau and S202-phosphorylated tau to | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |